Drug Trial Radar · NCT05561387
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
510
Planned (sponsor's estimate)
Start
Oct 12, 2023
Primary completion
May 30, 2031
Study completion May 30, 2031
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Sep 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which is given after initial treatment to help keep the cancer from coming back. There are three combinations of four different drugs being studied. Bortezomib is one of the drugs that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide works by helping bone marrow to produce normal blood cells and killing cancer cells. Anti-inflammatory drugs, such as dexamethasone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Daratumumab and hyaluronidase-fihj is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Patients receive 1 of 3 combinations of these drugs for treatment to determine which combination of study drugs works better to shrink and control multiple myeloma.
Conditions
- Plasma Cell Myeloma
Interventions
BortezomibDrug
Given SC
Daratumumab and Hyaluronidase-fihjDrug
Given SC
DexamethasoneDrug
Given PO
LenalidomideDrug
Given PO
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) of Arm 1 versus (vs.) Arm 2Time frame: From date of randomization to date of first documentation of progression or symptomatic deterioration, or death due to any cause, or assessed up to 10 years
- Overall survival (OS) of Arm 1 vs. Arm 3Time frame: From date of randomization to date of death due to any cause, or assessed up to 10 years
Locations
397 sites in 1 country. Site status is shown where the registry gives one.
Anchorage Associates in Radiation Medicine
Anchorage, Alaska · Recruiting
Anchorage Radiation Therapy Center
Anchorage, Alaska · Recruiting
Alaska Breast Care and Surgery LLC
Anchorage, Alaska · Recruiting
Alaska Oncology and Hematology LLC
Anchorage, Alaska · Recruiting
Alaska Women's Cancer Care
Anchorage, Alaska · Recruiting
Anchorage Oncology Centre
Anchorage, Alaska · Recruiting
Katmai Oncology Group
Anchorage, Alaska · Recruiting
Providence Alaska Medical Center
Anchorage, Alaska · Recruiting
Cancer Center at Saint Joseph's
Phoenix, Arizona · Recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Recruiting
CARTI Cancer Center
Little Rock, Arkansas · Recruiting
John L McClellan Memorial Veterans Hospital
Little Rock, Arkansas · Suspended
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California · Recruiting
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California · Recruiting
Marshall Cancer Center
Cameron Park, California · Recruiting
Mercy Cancer Center - Carmichael
Carmichael, California · Recruiting
Mercy San Juan Medical Center
Carmichael, California · Recruiting
Mercy Cancer Center - Elk Grove
Elk Grove, California · Recruiting
Fremont - Rideout Cancer Center
Marysville, California · Recruiting
Mercy UC Davis Cancer Center
Merced, California · Recruiting
Providence Queen of The Valley
Napa, California · Recruiting
Mercy Cancer Center - Rocklin
Rocklin, California · Recruiting
Mercy Cancer Center - Sacramento
Sacramento, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Pacific Central Coast Health Center-San Luis Obispo
San Luis Obispo, California · Recruiting
Mission Hope Medical Oncology - Santa Maria
Santa Maria, California · Recruiting
Providence Medical Foundation - Santa Rosa
Santa Rosa, California · Recruiting
Providence Santa Rosa Memorial Hospital
Santa Rosa, California · Recruiting
Gene Upshaw Memorial Tahoe Forest Cancer Center
Truckee, California · Recruiting
Woodland Memorial Hospital
Woodland, California · Recruiting
Rocky Mountain Regional VA Medical Center
Aurora, Colorado · Recruiting
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado · Recruiting
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado · Recruiting
Saint Francis Cancer Center
Colorado Springs, Colorado · Recruiting
Porter Adventist Hospital
Denver, Colorado · Suspended
Mercy Medical Center
Durango, Colorado · Recruiting
Southwest Oncology PC
Durango, Colorado · Recruiting
Saint Anthony Hospital
Lakewood, Colorado · Recruiting
Littleton Adventist Hospital
Littleton, Colorado · Suspended
Showing 40 of 397 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.